PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy
Jérémie Calais, Johannes Czernin
Abstract
![Figure][1]</img> Johannes Czernin ![Figure][1]</img> Jeremie Calais Approximately 20% of breast cancers express human epidermal growth factor receptor 2 (Erb-B2 receptor tyrosine kinase 2 [ERBB2], formerly HER2), and 70% express estrogen or progesterone receptors. All excised breast cancer
Topics & Concepts
BiomarkerEstrogen receptorCancer researchReceptor tyrosine kinaseTargeted therapyBreast cancerMedicineOncologyReceptorHuman Epidermal Growth Factor Receptor 2Tyrosine kinaseMetastatic breast cancerInternal medicineCancerBiologyBiochemistryProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsHER2/EGFR in Cancer Research